Emerging Infections Programs — CFDA 93.317

Surveillance-network obligations at $1.39 billion

USAspending.gov records $1,386,637,025.78 in obligations under CFDA 93.317. Thirty-one awards produce that stock. A simple average is about $44,730,226 per award — the largest per-row figure in this batch and consistent with multi-year site funding rather than small project grants. That average is a quotient of two packet totals, not a typical lab invoice and not a cost per case detected. Rounded, that stock is 1.4 billion in USAspending obligations.

The assistance-listing title is EMERGING INFECTIONS PROGRAMS. CFDA 93.317 is the identifier. Other infectious-disease listings tagged under different CFDA numbers are not mixed into the $1.39 billion. Combining those codes would invent a combined epidemiology total this packet does not contain.

30 recipients on a 24-jurisdiction map

Thirty recipients share 31 awards, or about 1.03 award records per recipient. Splitting $1,386,637,025.78 evenly would assign about $46.22 million per recipient. That near one-to-one density is a site-network pattern. The packet does not list the 30. Recipient count is the organizational headcount on the federal extract, not a census of hospitals, laboratories, or health departments in the network.

Twenty-four jurisdictions in the geographic count is a narrower map than most HHS listings nearby. Emerging-infections dollars still follow selected sites, not equal shares across all states. Place-of-performance amounts are on the program table.

Few awards, large tickets

Among HHS listings, 93.317 is an extreme-concentration file: 31 rows, 30 recipients, about $44.7 million per award. Award count is a weak proxy for “number of pathogens watched” and a worse proxy for cases. Recipients (30) tell you how many named organizations sit on the extract; awards (31) tell you how many assistance rows were stored.

The packet does not report isolates, outbreaks, or laboratory throughput. Citing 31 as surveillance sites completed or 24 as the only states with emerging infections would be a unit error. Keep the units straight: dollars, awards, recipients, jurisdictions.

Obligations versus surveillance outlays

The $1,386,637,025.78 is an obligation total from USAspending.gov. Outlays — cash paid against Emerging Infections Programs awards — are not in the packet. A network file can show a large obligation stock while annual site draws follow a later calendar. Deobligations and upward adjustments both move the total. A remaining-balance question is an outlay question this extract does not answer.

Use CFDA 93.317 to size this emerging-infections listing in the assistance file. Do not use it as an outbreak dashboard. Those series live elsewhere. This page reports the obligation book tagged 93.317.

What the 93.317 tables omit

The program hub lists award-backed obligations from USAspending.gov. It is not a case ledger, not a laboratory directory, and not a pathogen inventory. Series that never appear as assistance awards will not show up in the $1,386,637,025.78. That omission is definitional rather than a gap in the 31 award rows.

Place-of-performance on 24 jurisdictions is a coding field. Read the program page before treating those cells as the full surveillance map. Recipient dollars, if shown on the hub, are still obligation amounts, not cash already paid to sites.

A researcher comparing 93.317 with other infectious-disease codes should keep CFDA numbers separate. Twenty-four jurisdictions is a place-of-performance count for this listing, not the full map of emerging infections.

Where the 93.317 table lives

The program page overlays these four facts. The all-programs index ranks 93.317 among other assistance listings. Agency pages show awarding-agency rollups that may include this CFDA among other HHS listings. For 93.317 only, start on the program page.

CFDA 93.317’s 31 awards spread $1,386,637,025.78 across 30 recipients and 24 jurisdictions. Quote award count as a record count, recipient count as the organizational headcount, and dollars as obligations from USAspending.gov. About 1.03 award records per recipient is the density story on this listing. Outlays remain a separate column. Source: USAspending.gov assistance awards.

Emerging Infections Programs is a site-network listing: 31 awards, 30 recipients, 24 jurisdictions, about $44.7 million per award. That concentration is the fingerprint, not a pathogen count. Read the $1,386,637,025.78 as the USAspending obligation stock for CFDA 93.317 only.

Questions

How much is obligated for Emerging Infections Programs?

USAspending.gov records $1,386,637,025.78 in obligations for CFDA 93.317. SpendingVault indexes 31 awards, 30 recipients, and 24 jurisdictions. The figure is an obligation sum from assistance awards, not an outlay and not a case count. CFDA 93.317’s $1.39 billion is the USAspending obligation stock.

How many awards does CFDA 93.317 carry?

The listing shows 31 awards against 30 recipients, or about 1.03 award records per recipient. A simple average is about $44,730,226 per award. Award count is not a count of pathogens or laboratories. Recipient dollars are on the program page.

Why does 93.317 show only 24 jurisdictions?

The extract codes awards to 24 jurisdictions in the USAspending geographic field. That is a place-of-performance count for this listing, not a statement that emerging infections exist in only 24 states. Thirty recipients share the $1,386,637,025.78 stock. The packet does not name the 24.

Is $1.39 billion already paid to surveillance sites?

Not necessarily. Obligations are commitments. Outlays are payments. CFDA 93.317’s indexed total is the obligation stock from USAspending.gov. This page does not report cash drawn, remaining balances, or isolates sequenced. The $1,386,637,025.78 on 31 awards is the obligation figure.